RHHBY (RHHBY) Stock Price & Analysis
RHHBY (RHHBY) fell 1.07% to USD 50.01 as of June 9, 2026 at 23:56 UTC, according to Nexqual real-time market data.
RHHBY last closed at USD 50.55; the session ranged USD 49.47–50.4 on volume of 178,597 shares. Market capitalization is $322.11B, with a 52-week range of USD 37.51–60.85 (OQX). Source: Nexqual, June 9, 2026 at 23:56 UTC.
Key Statistics (as of June 9, 2026 at 23:56 UTC)
| Price | USD 50.01 |
|---|---|
| Change | ▼ 1.07% (down) |
| Previous Close | USD 50.55 |
| Open | USD 50.06 |
| Day Range | USD 49.47 – 50.4 |
| 52-Week Range | USD 37.51 – 60.85 |
| Volume | 178,597 shares |
| Market Cap | $322.11B |
| Exchange | OQX |
Technical Analysis (RHHBY)
Nexqual's technical model rates RHHBY "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:56 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.95 (neutral) |
| vs SMA50 | Below (USD 50.93) |
| MACD | -0.22 (negative) |
Analyst Ratings (RHHBY)
Wall Street analysts rate RHHBY "Buy" based on 7 analysts, with a mean price target of USD 56.66 (range USD 46–67), per Nexqual as of June 9, 2026 at 23:56 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 56.66 |
| High Target | USD 67 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 4 / 4 / 0 |
Earnings (RHHBY)
| Revenue Estimate | $15.60B |
|---|
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Financials & Fundamentals (RHHBY)
| Total Revenue | $63.36B |
|---|---|
| Revenue Growth (YoY) | -0.40% |
| Gross Margin | +74.49% |
| Operating Margin | +29.99% |
| Profit Margin | +20.33% |
| ROE | +37.27% |
| Debt / Equity | 87.64 |
| Current Ratio | 1.38 |
| Total Cash | $15.49B |
| Total Debt | $33.20B |
| Free Cash Flow | $11.03B |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Financial Health Score (RHHBY)
Nexqual rates RHHBY's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:56 UTC.
| Growth | Mixed — Revenue +1.7% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 74%, operating 30% |
| Balance Sheet | Mixed — $15.5B cash vs $33.2B debt |
| Cash Flow | Strong — FCF $11.0B, 18% margin |
| Efficiency | Strong — ROE 37%, ROA 12.9% |
Ownership (RHHBY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.79% |
| Shares Outstanding | 5.51B |
| Float | 5.22B |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Leadership (RHHBY)
RHHBY is led by Thomas Schinecker (age 50), Group Chief Executive Officer, per Nexqual as of June 9, 2026 at 23:56 UTC.
| Group Chief Executive Officer | Thomas Schinecker (age 50) |
|---|---|
| Executive Chairman | Severin Schwan (age 58) |
| Chief Financial Officer | Alan Hippe (age 58) |
Major Backers & Investors (RHHBY)
Notable institutional backers of RHHBY include Dodge & Cox Funds-Dodge & Cox Stock Fund, according to Nexqual as of June 9, 2026 at 23:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 0.24% |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVS | Novartis AG | USD 149.12 | ▼ 0.03% |
| SNY | Sanofi | USD 44.73 | ▼ 0.64% |
| NSRGY | Nestle S.A. | USD 97.42 | ▲ 1.04% |
| AZN | AstraZeneca PLC | USD 183.43 | ▼ 1.36% |
| GSK | GSK plc | USD 51.25 | ▼ 0.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:56 UTC. This page is informational and not investment advice.